patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_980617 | REC_0015101 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11 | 67 | female | 1 | 13 | 6.9 | 5 | sotorasib 960 mg daily | 8 | false | MSS | 2026-03-15T05:36:01.054177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984788 | REC_0015102 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.9 | 70 | female | 2 | 14 | 3.1 | 6 | sotorasib 960 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:36:01.054627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509469 | REC_0015103 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 14 | 7.2 | 80 | female | 3 | 14 | 3.8 | 2 | sotorasib 960 mg daily | 8.8 | true | MSS | 2026-03-15T05:36:01.054994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370682 | REC_0015104 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 17 | 76 | male | 3 | 24 | 3.2 | 6 | osimertinib 80 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:36:01.055341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583815 | REC_0015105 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 21.8 | 68 | female | 1 | 10 | 5.2 | 1 | sotorasib 960 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:36:01.055715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747545 | REC_0015106 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.2 | 65 | female | 0 | 85 | 7.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:36:01.056169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608988 | REC_0015107 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.6 | 64 | male | 0 | 7 | 5.5 | 5 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:36:01.056807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327744 | REC_0015108 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 31 | 5.9 | 66 | female | 0 | 44 | 5.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 43 | true | MSS | 2026-03-15T05:36:01.057231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803399 | REC_0015109 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5 | 72 | female | 1 | 29 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.9 | false | MSS | 2026-03-15T05:36:01.057603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740124 | REC_0015110 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.7 | 66 | female | 0 | 16 | 4.7 | 4 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:36:01.057979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276740 | REC_0015111 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.7 | 56 | female | 0 | 18 | 5.3 | 8 | sotorasib 960 mg daily | 16.8 | true | MSI-H | 2026-03-15T05:36:01.058382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652925 | REC_0015112 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 7.2 | 63 | female | 0 | 14 | 5.8 | 2 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:01.058768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871212 | REC_0015113 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.3 | 72 | female | 1 | 19 | 5.2 | 5 | sotorasib 960 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:36:01.059189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914025 | REC_0015114 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.9 | 61 | male | 0 | 6 | 5.1 | 4 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:36:01.059570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962987 | REC_0015115 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 10.8 | 64 | female | 1 | 4 | 5.8 | 7 | entrectinib 600 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:36:01.059994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476270 | REC_0015116 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.8 | 74 | female | 2 | 15 | 6.1 | 4 | alectinib 600 mg BID | 11.2 | true | MSS | 2026-03-15T05:36:01.060462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572605 | REC_0015117 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 5.2 | 71 | female | 1 | 21 | 3.6 | 6 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:01.060846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244376 | REC_0015118 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.8 | 71 | female | 2 | 16 | 5.3 | 4 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:36:01.061235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280881 | REC_0015119 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 9.3 | 58 | female | 0 | 18 | 5.6 | 7 | pembrolizumab 200 mg q3w | 10.3 | true | MSS | 2026-03-15T05:36:01.061605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574955 | REC_0015120 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.2 | 68 | female | 1 | 13 | 6.2 | 5 | sotorasib 960 mg daily | 12 | true | MSS | 2026-03-15T05:36:01.062142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141616 | REC_0015121 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.4 | 58 | male | 0 | 51 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:36:01.062549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374206 | REC_0015122 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 6 | 71 | female | 2 | 36 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.3 | false | MSS | 2026-03-15T05:36:01.062909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443909 | REC_0015123 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 15.5 | 69 | female | 1 | 11 | 4.8 | 6 | entrectinib 600 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:01.063284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607336 | REC_0015124 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.7 | 68 | female | 1 | 38 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:36:01.063658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988436 | REC_0015125 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.8 | 74 | female | 0 | 55 | 6 | 2 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:36:01.064006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789344 | REC_0015126 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 3.4 | 70 | female | 1 | 78 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.8 | true | MSS | 2026-03-15T05:36:01.064511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813652 | REC_0015127 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.3 | 69 | female | 0 | 17 | 4.5 | 2 | alectinib 600 mg BID | 17.8 | false | MSS | 2026-03-15T05:36:01.064917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219027 | REC_0015128 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.4 | 63 | male | 1 | 10 | 4.7 | 2 | osimertinib 80 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:36:01.065331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474766 | REC_0015129 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.4 | 65 | male | 1 | 26 | 5.9 | 3 | sotorasib 960 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:36:01.065722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926453 | REC_0015130 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 10 | 62 | female | 0 | 88 | 3.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:36:01.066073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770051 | REC_0015131 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.7 | 74 | male | 2 | 17 | 4.4 | 3 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:01.066490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968833 | REC_0015132 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 5.8 | 64 | male | 1 | 42 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:36:01.066904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725847 | REC_0015133 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.2 | 75 | female | 1 | 51 | 7.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:36:01.067466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645627 | REC_0015134 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 16.8 | 74 | female | 1 | 13 | 6.9 | 0 | alectinib 600 mg BID | 45.5 | true | MSS | 2026-03-15T05:36:01.067893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978805 | REC_0015135 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 14.1 | 67 | female | 0 | 18 | 7.7 | 5 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:36:01.069094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291189 | REC_0015136 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.5 | 68 | female | 1 | 15 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:36:01.069563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929362 | REC_0015137 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.1 | 62 | male | 1 | 20 | 5.6 | 3 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:36:01.069938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377414 | REC_0015138 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.9 | 63 | female | 1 | 19 | 6.8 | 2 | osimertinib 80 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:36:01.070293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173110 | REC_0015139 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.9 | 72 | female | 2 | 9 | 5.3 | 5 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:01.070692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912889 | REC_0015140 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10.1 | 79 | female | 1 | 15 | 5.7 | 7 | osimertinib 80 mg daily | 6 | false | MSI-H | 2026-03-15T05:36:01.071075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359278 | REC_0015141 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.8 | 69 | female | 0 | 67 | 5.6 | 8 | pembrolizumab 200 mg q3w | 15.7 | true | MSS | 2026-03-15T05:36:01.071479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573292 | REC_0015142 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.3 | 56 | male | 0 | 40 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:01.071887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680692 | REC_0015143 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.7 | 77 | female | 1 | 19 | 5.9 | 6 | sotorasib 960 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:36:01.072385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841682 | REC_0015144 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 12 | 66 | female | 1 | 26 | 5.2 | 10 | osimertinib 80 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:36:01.072810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823326 | REC_0015145 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 8.4 | 70 | female | 1 | 17 | 4.6 | 2 | entrectinib 600 mg daily | 20.9 | false | MSS | 2026-03-15T05:36:01.073213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664765 | REC_0015146 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.9 | 60 | male | 1 | 12 | 3.9 | 5 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:01.073842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140789 | REC_0015147 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 1.5 | 71 | female | 2 | 29 | 5.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:36:01.074260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408641 | REC_0015148 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 18 | 66 | male | 0 | 11 | 3.7 | 6 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:36:01.074660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823403 | REC_0015149 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.6 | 61 | female | 0 | 20 | 4.2 | 1 | osimertinib 80 mg daily | 25.6 | false | MSI-H | 2026-03-15T05:36:01.075057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778064 | REC_0015150 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 16.3 | 72 | female | 2 | 27 | 3.8 | 4 | sotorasib 960 mg daily | 7.5 | false | MSS | 2026-03-15T05:36:01.075463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918967 | REC_0015151 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.6 | 74 | female | 1 | 15 | 6.2 | 4 | sotorasib 960 mg daily | 10.8 | true | MSS | 2026-03-15T05:36:01.075880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864135 | REC_0015152 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 7 | 73 | male | 2 | 12 | 4.9 | 1 | alectinib 600 mg BID | 29.3 | false | MSS | 2026-03-15T05:36:01.076398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503924 | REC_0015153 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 17.2 | 73 | female | 0 | 16 | 3.5 | 5 | alectinib 600 mg BID | 6.5 | false | MSI-H | 2026-03-15T05:36:01.076827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395409 | REC_0015154 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16.2 | 62 | male | 0 | 12 | 6 | 6 | sotorasib 960 mg daily | 12.4 | true | MSS | 2026-03-15T05:36:01.077221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807120 | REC_0015155 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 2.8 | 66 | female | 0 | 10 | 5.7 | 2 | osimertinib 80 mg daily | 28.9 | true | MSS | 2026-03-15T05:36:01.077592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861258 | REC_0015156 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.7 | 65 | male | 1 | 48 | 6.3 | 1 | pembrolizumab 200 mg q3w | 16.7 | false | MSS | 2026-03-15T05:36:01.077956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816114 | REC_0015157 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 9.7 | 73 | female | 2 | 15 | 6.2 | 1 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:01.078369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133901 | REC_0015158 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.5 | 68 | female | 1 | 9 | 5.8 | 5 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:36:01.078753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684869 | REC_0015159 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 16.4 | 68 | female | 0 | 5 | 6.2 | 6 | osimertinib 80 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:36:01.079378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368493 | REC_0015160 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.7 | 65 | male | 0 | 14 | 4.4 | 4 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:36:01.079838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602032 | REC_0015161 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.8 | 62 | male | 1 | 16 | 6.4 | 6 | alectinib 600 mg BID | 5.5 | true | MSI-H | 2026-03-15T05:36:01.080486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870216 | REC_0015162 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 13.7 | 75 | female | 1 | 11 | 3.2 | 2 | sotorasib 960 mg daily | 26.2 | true | MSS | 2026-03-15T05:36:01.080954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133180 | REC_0015163 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 18.1 | 57 | male | 0 | 24 | 6.4 | 0 | sotorasib 960 mg daily | 36.2 | false | MSS | 2026-03-15T05:36:01.081682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577147 | REC_0015164 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.8 | 77 | female | 1 | 13 | 6.9 | 4 | entrectinib 600 mg daily | 6.5 | false | MSS | 2026-03-15T05:36:01.082365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116941 | REC_0015165 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.1 | 54 | male | 0 | 49 | 5.9 | 5 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:36:01.082829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599154 | REC_0015166 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9.4 | 74 | female | 2 | 13 | 3.8 | 5 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:01.083195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363486 | REC_0015167 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 31 | 5.5 | 61 | female | 1 | 12 | 6 | 2 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:01.083556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966848 | REC_0015168 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.9 | 70 | male | 1 | 65 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.2 | false | MSS | 2026-03-15T05:36:01.083942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322646 | REC_0015169 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.8 | 59 | male | 1 | 10 | 5.6 | 6 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:01.084461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594448 | REC_0015170 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.1 | 66 | female | 0 | 26 | 4.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:36:01.084882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104493 | REC_0015171 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 10.2 | 64 | male | 0 | 21 | 3 | 2 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:01.085345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817202 | REC_0015172 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 11.9 | 67 | female | 0 | 13 | 5 | 0 | osimertinib 80 mg daily | 42.7 | false | MSS | 2026-03-15T05:36:01.085939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978364 | REC_0015173 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 12.3 | 82 | male | 0 | 15 | 4.3 | 3 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:36:01.086422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900751 | REC_0015174 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 19.6 | 70 | female | 2 | 12 | 4.7 | 5 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:01.086857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243740 | REC_0015175 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.6 | 62 | female | 0 | 19 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | true | MSS | 2026-03-15T05:36:01.087291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939246 | REC_0015176 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 5.3 | 60 | female | 0 | 12 | 6.8 | 2 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:36:01.087693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291418 | REC_0015177 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 6.3 | 86 | female | 1 | 59 | 5.9 | 6 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:36:01.088179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657354 | REC_0015178 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 15 | 51 | female | 0 | 8 | 7.5 | 2 | entrectinib 600 mg daily | 15.5 | true | MSS | 2026-03-15T05:36:01.088656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347858 | REC_0015179 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 5.4 | 81 | female | 0 | 6 | 7.1 | 2 | sotorasib 960 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:01.089062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858583 | REC_0015180 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.3 | 61 | female | 1 | 19 | 5.5 | 2 | sotorasib 960 mg daily | 6.6 | true | MSS | 2026-03-15T05:36:01.089474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917175 | REC_0015181 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 11.6 | 64 | female | 0 | 24 | 7.2 | 2 | alectinib 600 mg BID | 8 | false | MSI-H | 2026-03-15T05:36:01.089866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819235 | REC_0015182 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 13.5 | 52 | female | 0 | 11 | 3.9 | 2 | entrectinib 600 mg daily | 26.6 | false | MSI-H | 2026-03-15T05:36:01.090271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294334 | REC_0015183 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.6 | 67 | female | 1 | 8 | 5.2 | 2 | sotorasib 960 mg daily | 4.4 | true | MSS | 2026-03-15T05:36:01.090656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734665 | REC_0015184 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.3 | 69 | female | 1 | 8 | 5.4 | 7 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:01.091043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633268 | REC_0015185 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 3.4 | 80 | male | 1 | 63 | 6.4 | 1 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:36:01.091607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651852 | REC_0015186 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 14.9 | 78 | female | 2 | 0 | 5 | 2 | alectinib 600 mg BID | 16.9 | false | MSI-H | 2026-03-15T05:36:01.092021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646497 | REC_0015187 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14.4 | 68 | female | 1 | 3 | 6.9 | 2 | alectinib 600 mg BID | 17.4 | true | MSS | 2026-03-15T05:36:01.094052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772614 | REC_0015188 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.2 | 74 | female | 0 | 28 | 6.5 | 5 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:36:01.094482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153208 | REC_0015189 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 9.4 | 82 | female | 0 | 11 | 5.4 | 1 | alectinib 600 mg BID | 17 | false | MSS | 2026-03-15T05:36:01.094877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464630 | REC_0015190 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 14 | 61 | female | 0 | 12 | 5.9 | 6 | entrectinib 600 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:36:01.095258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647746 | REC_0015191 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 17.6 | 67 | female | 0 | 12 | 7.3 | 6 | pembrolizumab 200 mg q3w | 12.8 | true | MSS | 2026-03-15T05:36:01.095637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934153 | REC_0015192 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 7.1 | 62 | female | 1 | 12 | 4.5 | 1 | pembrolizumab 200 mg q3w | 23.4 | false | MSS | 2026-03-15T05:36:01.096023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429481 | REC_0015193 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.2 | 59 | female | 1 | 40 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | true | MSS | 2026-03-15T05:36:01.096491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827939 | REC_0015194 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.2 | 85 | female | 2 | 16 | 5 | 1 | alectinib 600 mg BID | 7.2 | false | MSS | 2026-03-15T05:36:01.096915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618387 | REC_0015195 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.8 | 68 | female | 0 | 17 | 5.7 | 4 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:36:01.097352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770386 | REC_0015196 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 19 | 64 | male | 0 | 18 | 3.6 | 5 | pembrolizumab 200 mg q3w | 8.9 | true | MSI-H | 2026-03-15T05:36:01.097734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938920 | REC_0015197 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.1 | 58 | male | 1 | 30 | 4.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.8 | true | MSS | 2026-03-15T05:36:01.098308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856940 | REC_0015198 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.7 | 71 | female | 1 | 66 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:36:01.098991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960312 | REC_0015199 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 14 | 8.8 | 62 | male | 0 | 42 | 7.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:36:01.099454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445884 | REC_0015200 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.2 | 65 | male | 1 | 10 | 5.6 | 5 | alectinib 600 mg BID | 9.8 | false | MSS | 2026-03-15T05:36:01.099852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.